CR2
Complement receptor type 2
Protein Summary
Receptor for complement C3Dd, for the Epstein-Barr virus on human B-cells and T-cells and for HNRNPU (PubMed:7753047). Participates in B lymphocytes activation (PubMed:7753047). (Microbial infection) Acts as a receptor for Epstein-Barr virus. This gene encodes a membrane protein, which functions as a receptor for Epstein-Barr virus (EBV) binding on B and T lymphocytes. Genetic variations in this gene are associated with susceptibility to systemic lupus erythematosus type 9 (SLEB9). Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Sep 2009]
- ENST00000367057
- ENSP00000356024
- ENSG00000117322
- ENST00000367058
- ENSP00000356025
- C3DR
- CR
- C3DR
- CD21
- CVID7
- SLEB9
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
gene perturbation | 0.89 | ||
biological term | 0.81 | ||
disease | 0.63 | ||
transcription factor | 0.63 | ||
histone modification site profile | 0.62 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1227.96 (req: < 5)
Gene RIFs: 97 (req: <= 3)
Antibodies: 1245 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1227.96 (req: >= 5)
Gene RIFs: 97 (req: > 3)
Antibodies: 1245 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 12
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0